Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A post-hoc analysis of RELIght study.
Papaioannou AI, Kallieri M, Zervas E, Fouka E, Porpodis K, Hadji Mitrova M, Tzortzaki E, Makris M, Ntakoula M, Lyberopoulos P, Dimakou K, Koukidou S, Ampelioti S, Papaporfyriou A, Katsoulis K, Kipourou M, Rovina N, Antoniou K, Vittorakis S, Bakakos P, Steiropoulos P, Markopoulou K, Avarlis P, Papanikolaou ΙC, Markatos M, Gaki E, Samitas K, Glynos K, Papiris SA, Papakosta D, Tzanakis N, Gaga M, Kostikas K, Loukides S. Papaioannou AI, et al. Among authors: tzortzaki e. Allergy Asthma Proc. 2025 Jan 1;46(1):45-51. doi: 10.2500/aap.2025.46.240084. Allergy Asthma Proc. 2025. PMID: 39741370
Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.
Kallieri M, Papaioannou AI, Zervas E, Fouka E, Porpodis K, Hadji Mitrova M, Tzortzaki E, Makris M, Ntakoula M, Lyberopoulos P, Dimakou K, Koukidou S, Ampelioti S, Papaporfyriou A, Katsoulis K, Kipourou M, Rovina N, Antoniou K, Vittorakis S, Bakakos P, Steiropoulos P, Markopoulou K, Avarlis P, Papanikolaou ΙC, Markatos M, Gaki E, Samitas K, Glynos K, Papiris SA, Papakosta D, Tzanakis N, Gaga M, Kostikas K, Loukides S. Kallieri M, et al. Among authors: tzortzaki e. Clin Exp Allergy. 2024 Apr;54(4):286-290. doi: 10.1111/cea.14436. Epub 2023 Dec 12. Clin Exp Allergy. 2024. PMID: 38084474 No abstract available.
RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response.
Kallieri M, Zervas E, Fouka E, Porpodis K, Mitrova MH, Tzortzaki E, Makris M, Ntakoula M, Papaioannou AI, Lyberopoulos P, Dimakou K, Koukidou S, Ampelioti S, Papaporfyriou A, Katsoulis K, Kipourou M, Rovina N, Antoniou K, Vittorakis S, Bakakos P, Steiropoulos P, Markopoulou K, Avarlis P, Papanikolaou ΙC, Markatos M, Gaki E, Samitas K, Glynos K, Papiris SA, Papakosta D, Tzanakis N, Gaga M, Kostikas K, Loukides S. Kallieri M, et al. Among authors: tzortzaki e. Allergy. 2022 Sep;77(9):2848-2852. doi: 10.1111/all.15382. Epub 2022 May 30. Allergy. 2022. PMID: 35595723 No abstract available.
Economic Evaluation of Omalizumab Compared With Standard Therapy in the Treatment of Severe Allergic Asthma in Adult Patients in Greece: a Cost Effectiveness Analysis Based on Clinical Trial and Real-World Data.
Sonathi V, Hatzikou M, Baldwin M, Panitti E, Tzortzaki E. Sonathi V, et al. Among authors: tzortzaki e. Value Health. 2014 Nov;17(7):A597-8. doi: 10.1016/j.jval.2014.08.2065. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202057 Free article. No abstract available.
Frequent exacerbators--a distinct phenotype of severe asthma.
Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, Nizankowska-Mogilnicka E, Gjomarkaj M, Gaga M, Brusselle G, Dahlén B, Dahlén SE; BIOAIR investigators. Kupczyk M, et al. Clin Exp Allergy. 2014 Feb;44(2):212-21. doi: 10.1111/cea.12179. Clin Exp Allergy. 2014. PMID: 24447083 Free article. Clinical Trial.
61 results